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Summary
 
It has been established that insulin-dependent diabetes mellitus (IDDM) in nonobese diabetic
(NOD) mice results from a CD4
 
1
 
 and CD8
 
1
 
 T cell–dependent autoimmune process directed
against the pancreatic beta cells. The precise roles that beta cell–reactive CD8
 
1
 
 and CD4
 
1
 
 T cells
play in the disease process, however, remain ill defined. Here we have investigated whether na-
ive beta cell–specific CD8
 
1
 
 and CD4
 
1
 
 T cells can spontaneously accumulate in pancreatic is-
lets, differentiate into effector cells, and destroy beta cells in the absence of other T cell speci-
ficities. This was done by introducing K
 
d
 
– or I-A
 
g7
 
–restricted beta cell–specific T cell receptor
(TCR) transgenes that are highly diabetogenic in NOD mice (8.3- and 4.1-TCR, respec-
tively), into recombination-activating gene (RAG)-2–deficient NOD mice, which cannot re-
arrange endogenous TCR genes and thus bear monoclonal TCR repertoires. We show that
while RAG-2
 
2
 
/
 
2
 
 4.1-NOD mice, which only bear beta cell–specific CD4
 
1
 
 T cells, develop
diabetes as early and as frequently as RAG-2
 
1
 
 4.1-NOD mice, RAG-2
 
2
 
/
 
2
 
 8.3-NOD mice,
which only bear beta cell–specific CD8
 
1
 
 T cells, develop diabetes less frequently and signifi-
cantly later than RAG-2
 
1
 
 8.3-NOD mice. The monoclonal CD8
 
1
 
 T cells of RAG-2
 
2
 
/
 
2
 
 8.3-
NOD mice mature properly, proliferate vigorously in response to antigenic stimulation in vitro,
and can differentiate into beta cell–cytotoxic T cells in vivo, but do not efficiently accumulate
in islets in the absence of a CD4
 
1
 
 T cell–derived signal, which can be provided by splenic
CD4
 
1
 
 T cells from nontransgenic NOD mice. These results demonstrate that naive beta cell–
specific CD8
 
1
 
 and CD4
 
1
 
 T cells can trigger diabetes in the absence of other T or B cell speci-
ficities, but suggest that efficient recruitment of naive diabetogenic beta cell–reactive CD8
 
1
 
 T cells
to islets requires the assistance of beta cell–reactive CD4
 
1
 
 T cells.
 
I
 
nsulin-dependent diabetes mellitus (IDDM)
 
1
 
 in non-
obese diabetic (NOD) mice, which spontaneously de-
velop a form of diabetes closely resembling human IDDM,
is the result of a CD4
 
1
 
 and CD8
 
1
 
 T cell–dependent au-
toimmune process directed against the pancreatic beta cells
(1, 2). Although the role of T cells as effectors of beta cell
damage in IDDM is well established, the nature of the cells
and immunological mechanisms that initiate diabetogenesis
in genetically susceptible mice remain to be elucidated.
Adoptive T cell transfer studies using spleen cells from
prediabetic NOD mice have demonstrated that transfer of
IDDM into immunodeficient NOD mice requires both
CD4
 
1
 
 and CD8
 
1
 
 T cells (3–6). However, splenic CD4
 
1
 
T cells from NOD mice and some, though not all, preacti-
vated I-A
 
g7
 
–restricted, beta cell–specific CD4
 
1
 
 T cell
clonotypes can home into pancreatic islets and destroy beta
cells in the absence of CD8
 
1
 
 T cells (6–13). Since beta cells
do not express MHC class II molecules (I-A
 
g7
 
; references
14, 15), it has been proposed that naive autoreactive CD4
 
1
 
T cells may differentiate into effector cells by engaging au-
toantigens that are purportedly shed from the beta cells by a
yet to be determined initial insult, in the context of I-A
 
g7
 
molecules on local APCs (1, 16).
Studies of 
 
b
 
2-microglobulin–deficient NOD mice (17–
19) and anti-CD8 mAb-treated NOD mice (20), which do
not bear mature CD8
 
1
 
 T cells and develop neither diabetes
nor insulitis, have suggested that development of insulitis in
NOD mice is somehow regulated by CD8
 
1
 
 T cells. Al-
though these studies could not rule out a general influence
of MHC class I molecules and/or CD8
 
1
 
 T cells on the in-
sulitogenic activity of naive autoreactive CD4
 
1
 
 T cells (20),
they argued in favor of the hypothesis that the initial beta
cell insult that triggers the shedding of beta cell autoanti-
 
1
 
Abbreviations used in this paper:
 
 CM, complete medium; HPRT, hypoxan-
thine phosphoribosyl transferase; IDDM, insulin-dependent diabetes mel-
litus; NOD, nonobese diabetic; RAG, recombination-activating gene.
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gens and subsequent CD4
 
1
 
 T cell activation may be medi-
ated by beta cell–cytotoxic CD8
 
1
 
 T cells, which are con-
sistently present in pancreatic islets of NOD mice (16, 21–
26). This view is compatible with two other observations:
that restoring expression of MHC class I molecules on beta
cells of 
 
b
 
2-microglobulin–deficient NOD mice restores in-
sulitis susceptibility (27), and that splenocytes from predia-
betic NOD mice cannot efficiently transfer insulitis into 
 
b
 
2-
microglobulin–deficient NOD.
 
scid
 
 mice (28).
This hypothesis, however, is in apparent conflict with other
observations that support the alternative view that diabeto-
genesis is initiated by MHC class II–restricted autoreactive
CD4
 
1
 
 T cells. For example, splenic CD4
 
1
 
 T cells from
prediabetic NOD mice can transfer insulitis into NOD.
 
scid
 
mice without CD8
 
1
 
 T cell cotransfer, and splenic CD8
 
1
 
 T
cells from diabetic NOD mice cannot home into pancre-
atic islets of irradiated NOD mice or NOD.
 
scid
 
 mice in the
absence of CD4
 
1
 
 T cells (6, 29). Furthermore, since beta
cells do not express the costimulatory B7.1 or B7.2 mole-
cules (30), naive beta cell–specific MHC class I–restricted
CD8
 
1
 
 T cells are unlikely to differentiate into cells capable
of effecting beta cell damage unless their target beta cell au-
toantigens are shed from the beta cell by an earlier insult,
and later presented to them by APCs capable of processing
exogenous antigens through the MHC class I pathway. Fi-
nally, and most importantly, genetic susceptibility and resis-
tance to both insulitis and IDDM are profoundly affected
by polymorphisms of MHC class II genes (2, 31), which
control the development and function of CD4
 
1
 
, but not
CD8
 
1
 
, T cells.
The autoreactive T cells that affect the initial beta cell
insult in spontaneous IDDM should be able to home into
pancreatic islets, differentiate into effector cells, and effect
beta cell damage in the absence of other T cells. To investi-
gate the independent insulitogenic and diabetogenic poten-
tial of naive beta cell–reactive CD4
 
1
 
 or CD8
 
1
 
 T cells in
spontaneous IDDM, we have compared the ability of NOD
mouse islet-derived, I-A
 
g7
 
– or K
 
d
 
–restricted, beta cell–spe-
cific TCRs to: (
 
a
 
) accelerate diabetogenesis in TCR-trans-
genic NOD mice, and (
 
b
 
) trigger insulitis and diabetes in
TCR-transgenic, recombination-activating gene (RAG)-
2
 
2
 
/
 
2
 
 NOD mice, which cannot rearrange endogenous
TCR genes and thus bear monoclonal TCR repertoires.
We show that unlike naive diabetogenic CD4
 
1
 
 T cells,
which require neither mature B cells nor CD8
 
1
 
 T cells to
accumulate in islets and destroy beta cells, naive diabetoge-
nic CD8
 
1
 
 T cells are largely dependent on CD4
 
1
 
 T cells to
efficiently accumulate in pancreatic islets and cause diabe-
tes. On the basis of these findings, we propose that recruit-
ment of the first autoreactive CD8
 
1
 
 T cells into pancreatic
islets of NOD mice is preceded and/or accompanied by the
recruitment of autoreactive CD4
 
1
 
 T cells.
 
Materials and Methods
 
Production of TCR-transgenic, RAG-2
 
2
 
/
 
2
 
 NOD Mice.
 
The
H-2K
 
d
 
–restricted, beta cell–cytotoxic CD8
 
1
 
 T cell clone NY8.3
was chosen as donor of TCR-
 
a
 
 (V
 
a
 
n.1-J
 
a
 
34) and TCR-
 
b
 
 trans-
genes (V
 
b
 
8.1-D
 
b
 
2.1-J
 
b
 
2.4) to generate 8.3-NOD mice. This T
cell clone was isolated from islets of an acutely diabetic NOD mouse
(24), uses a TCR-
 
a
 
–CDR3 sequence homologous or identical to
those used by many NOD islet-derived beta cell–cytotoxic CD8
 
1
 
T cells (25, 26), and is diabetogenic in adoptive T cell transfer ex-
periments (24, 32). 4.1-NOD mice (expressing the TCR-
 
a
 
 and
-
 
b
 
 rearrangements of the I-A
 
g7
 
–restricted beta cell–specific CD4
 
1
 
T cell clone NY4.1) and 8.3–TCR-
 
b
 
–transgenic NOD mice (ex-
pressing the TCR-
 
b
 
 rearrangement of NY8.3) are described else-
where (26, 33). Transgenic constructs bearing the functional
VDJ
 
b
 
 and VJ
 
a
 
 rearrangements of NY8.3 (25), upstream regula-
tory sequences, and the TCR-
 
b
 
 enhancer (for the TCR-
 
b
 
 con-
struct) or the TCR-
 
a
 
 or IgH enhancers (for the TCR-
 
a
 
 con-
struct) were generated as described (26, 33). After removing
prokaryotic sequences by digestion with PvuI and SalI (TCR-
 
b
 
),
ClaI and SacII (TCR-
 
a
 
–IgHenh), or ClaI and SalI (TCR-
 
a
 
–
 
a
 
enh),
the constructs (21.5, 12.7, or 14.5 kb, respectively) were coin-
jected into fertilized (SJL 
 
3
 
 C57BL/6) F2 eggs (DNX, Princeton,
NJ). Offspring were screened for integration of the transgenes by
Southern blotting using VDJ
 
b
 
 and VJ
 
a
 
 cDNA probes. Two
transgenic founder mice expressing the transgenes (8.3–AN6B7–
TCR-
 
a
 
/
 
b
 
 with the TCR-
 
a
 
–
 
a
 
enh construct, and 8.3–IgH3A–
TCR-
 
a
 
/
 
b
 
 with the TCR-
 
a
 
–IgHenh construct) were backcrossed
with NOD/Lt mice (I-A
 
g7
 
, I-E
 
2
 
, K
 
d
 
, D
 
b
 
, from The Jackson Lab-
oratory, Bar Harbor, ME) for three to six generations to generate
8.3–TCR-
 
a
 
/b–transgenic NOD (8.3-NOD) mice. Studies of
mice derived from these two different founders yielded similar
results.
RAG-22/2 NOD mice were generated by backcrossing the
RAG-2 mutation of RAG-22/2 C57BL/6 mice (34; a gift from
F. Alt, Boston Children’s Hospital, Boston, MA) onto the NOD
background for 10 generations, followed by intercrossing of N10
heterozygotes. RAG-22/2 4.1-NOD and RAG-22/2 8.3-NOD
mice (also referred to as monoclonal T cell NOD mice) were gen-
erated by backcrossing the TCR transgenes of 4.1-NOD and 8.3-
NOD mice onto RAG-22/2 NOD mice. Mice were screened
for inheritance of the transgenes and mutated or wild-type RAG-2
alleles by PCR of tail DNA. All mice were housed in a specific
pathogen-free facility at The University of Calgary.
Cell Lines, Antibodies, and Flow Cytometry. H-2Kd–transfected
L929 cells (L929-Kd) were obtained from J. Yewdell (National
Institutes of Health, Bethesda, MD). NOD mouse–derived NIT-1
and MIN6N8a insulinoma cells were provided by E.H. Leiter (The
Jackson Laboratory) and J.-I. Miyazaki (University of Tokyo,
Tokyo, Japan), respectively. WEHI-164 clone 13 cells were pro-
vided by D. Remick (University of Michigan, Ann Arbor, MI).
A hybridoma secreting the Vb8.1/8.2-specific mAb KJ16 was a
gift from P. Marrack (National Jewish Center for Immunology,
Denver, CO). Hybridomas secreting mAbs 1411-2C11 (anti-CD3),
GK1.5 (anti-CD4), RA3-6B2 (anti-CD45RA/B220), F4/80 (anti-
macrophage), and M1/70.15.11.5.HL (anti–Mac-1) were ob-
tained from the American Type Culture Collection (Rockville,
MD). Anti-Lyt-2 (CD8a)-PE (53-6.7), anti-L3T4-FITC or anti-
L3T4-biotin (CD4) (H129.19), anti-CD2-biotin (RM2-5), anti-
CD5 (53-7.3)-biotin, anti-CD11a-biotin (M17/4), anti-CD24-
biotin (M1/69), anti-CD28-biotin (37.51), anti-CD44-FITC (IM7),
anti-CD45RB-FITC (23G2), anti-L-selectin-biotin (CD62L)
(MEL-14), anti-CD69-biotin (H1.2F3), anti-Vb8.1/8.2-FITC
(MR5-2), and anti-H-2Kd-FITC (SF1-1.1) were purchased from
PharMingen (San Diego, CA). Anti-IL-2R-FITC (CD25)
(AMT13) was purchased from Cedarlane Laboratories (Hornby,
Ontario, Canada). Mouse IgG-absorbed FITC-conjugated goat
anti–rat IgG and FITC-conjugated goat anti–mouse IgG were1665 Verdaguer et al.
obtained from CALTAG (San Francisco, CA) and Becton Dick-
inson (San Jose, CA), respectively. Streptavidin-PerCP was ob-
tained from Becton Dickinson. Thymi, spleens, and islet-derived
T cell lines were analyzed by three-color flow cytometry using a
FACScanÒ (Becton Dickinson) as described elsewhere (26).
TNF-a Secretion. Splenocytes from 8.3-NOD mice were de-
pleted of CD41 T cells using anti-CD4 mAb (GK-1.5)–coated
magnetic beads, as described (26). The remaining cells were ana-
lyzed by flow cytometry and adjusted to 104 CD81 T cells/100
ml of complete medium (CM; RPMI 1640 media containing
10% heat-inactivated fetal bovine serum [GIBCO BRL, Gaith-
ersburg, MD], 50 U/ml penicillin, 50 mg/ml streptomycin (Flow
Laboratories, McLean, VA), and 50 mM 2-ME [Sigma Chemical
Co., St. Louis, MO]) and challenged with beta cells (NIT-1 or
MIN6N8a) or control target cells (L929-Kd) (104 cells/100 ml)
for 24 h. The culture supernatants (100 ml) were assayed for the
presence of TNF-a by measuring their cytolytic effect on WEHI-
164 clone 13 cells (35) using a colorimetric assay (Cell Prolifera-
tion Kit II, Boehringer Mannheim, Mannheim, Germany).
rTNF-a (R&D Systems, Minneapolis, MN) was used to generate
the standard curves. In some experiments, splenic CD81 T cells
were preactivated with plate-bound anti-CD3 mAb (1411-2C11,
10 mg/ml) for 3 d at 378C in 5% CO2 (26) and expanded with
0.5 U/ml of rIL-2 (Takeda, Osaka, Japan) for 7 d before being as-
sayed for their ability to secrete TNF-a in response to beta cells.
Proliferation Assays. Pancreatic islet cells were prepared from
5–8-wk-old NOD mice as described (26). Splenic CD81 T cells
(2 3 104) were incubated, in triplicate, with g-irradiated (3,000
rad) islet cells (3–100 3 103/well) in 96–round-bottomed well
tissue culture plates for 3 d at 378C in 5% CO2. Cultures were
pulsed with 1 mCi of [3H]thymidine during the last 18 h of cul-
ture and harvested. Thymidine incorporation was measured by scin-
tillation counting. Specific proliferation was calculated by sub-
stracting background proliferation (cpm of cultures containing
islet cells alone and cpm of cultures of T cells alone) from islet
cell–induced proliferation (cpm of cultures containing T cells and
islet cells). For anti–TCR-b stimulation, CD81 T cells (2 3 104)
were added, in triplicate, to ELISA-grade wells precoated with
10-fold serial dilutions of KJ16 mAb (anti-Vb8.1/8.2)–contain-
ing ascites (1:10–1:10,000; reference 26), incubated for 48 h,
pulsed with [3H]thymidine for 18 h, harvested, and analyzed by
scintillation counting.
Limiting Dilution Analyses. To determine the peripheral fre-
quency of beta cell–reactive CD81 T cells, 12 replicate cultures
of 10-fold serial dilutions of splenocytes (101–105 cells/well) were
stimulated with irradiated (2,500 rads) NOD islets (8/well) for 4 d,
expanded in rIL-2 (0.5 U/ml) for 10 d, and restimulated with is-
lets and rIL-2. Control plates received rIL-2, but not islets. The
resulting cultures were split, challenged with 104 NIT-1 cells or
L929-Kd cells for 24 h, and the supernatants were collected to
measure the contents of TNF-a. Cultures that secreted TNF-a
in response to MIN6N8a cells (absorbance values two standard
deviations below the average values of control cultures) but not
L929-Kd cells were considered to contain beta cell–reactive CD81
T cells. Frequencies were calculated by Poisson statistics.
Generation of Spleen- and Islet-derived CD81 T Cell Lines and
Clones. CD41 T cell–depleted spleen cells (104 cells/well in 96-
well plates) were stimulated with irradiated NOD islets for 3 d,
and the activated cells expanded with 0.5 U/ml rIL-2 for 10–14 d.
Growing cultures were split and individual subcultures assayed at
this point for serine esterase content (see below) or beta cell reac-
tivity.
Islet-infiltrating CD81 T cell lines were isolated from predia-
betic or acutely diabetic mice as described previously (26). In brief,
isolated islets were cultured in CM containing 0.5 U/ml of rIL-2,
and the lymphocytes obtained after 4–5 d were analyzed by flow
cytometry to determine their phenotype, depleted of CD41 T cells
by negative selection with GK1.5 mAb-coated immunobeads, used
for messenger RNA extraction, cloned in 96-well plates under lim-
iting dilution conditions (1–5 cells/well), and stimulated once with
irradiated NOD islets in the presence of rIL-2. Growing cultures
were split into three subcultures and assayed within 10 d of clon-
ing for beta cell specificity (TNF-a release in response to NIT-1
or L929-Kd cells) and serine esterase content, or expanded fur-
ther to obtain sufficient cells for cytotoxicity assays.
Determination of Serine Esterase Content. Confluent 96-well plate
subcultures were lysed with 1% Triton X-100 and the lysates ana-
lyzed for serine esterase activity (26, 36). Absorbance readings two
standard deviations above the mean of negative cultures (non-
stimulated splenocytes) were considered positive.
Cytokine Reverse Transcription-PCR. Total cellular RNA was
extracted from islet-derived T cell lines depleted of CD41 T cells
(.98% CD81) by the guanidium isothiocyanate-phenol-chloro-
form method, and 2 mg used in a reverse transcription reaction
using oligo(dT)12–18 (GIBCO BRL) as a primer. The cDNAs were
amplified by PCR using previously described primers specific for
several cytokines, including IL-2, IFN-g, IL-4, IL-10, TNF-a,
and for hypoxanthine phosphoribosyl transferase (HPRT) as in-
ternal control (37). The PCR products were electrophoresed in a
1.5% agarose gel and detected by ethidium bromide staining.
51Cr–Release Assays. Single islet cells (5 3 105) from NOD
(H-2g7: I-Ag7, Kd, Db) and C57BL/6 (H-2b: I-Ab, Kb, Db) mice
were labelled with [51Cr]sodium chromate (DuPont New En-
gland Nuclear, Boston, MA), resuspended at 105 cells/ml, and
seeded at 104 cells/100 ml/well. Effector cells (islet-derived CD81
T cell clones) were added to each well, in duplicate, at several tar-
get/effector ratios. Plain medium was added to a set of target cells
for examination of spontaneous cell lysis. Total cell lysis was de-
termined by lysing the cells with 1% Triton X-100. The plates
were centrifuged at 100 g for 3 min and incubated at 378C for 8 h.
After incubation, the plates were centrifuged and the supernatants
(100 ml) harvested. The radioactivity of the supernatants was mea-
sured in a gamma counter (LKB-Wallac, Turku, Finland). Spe-
cific 51Cr release was calculated as follows: percent lysis 5 100 3
(test cpm 2 spontaneous cpm)/(total cpm 2 spontaneous cpm).
Adoptive T cell Transfer. Splenocytes from 4–5-wk-old non-
transgenic female NOD mice were depleted of CD81 T cells us-
ing anti-CD8 mAb (53-6.7)–coated magnetic beads (26). The re-
maining cells (containing ,0.5% CD81 T cells) were injected
(8 3 106 cells/mouse) into 5–8-wk-old female RAG-22/2 8.3-
NOD mice. Recipient mice were monitored for diabetes or
killed 10 wk after transfer for histology. Some RAG-22/2 8.3-
NOD mice were transfused with splenic T cells from nontrans-
genic NOD mice (1.5 3 107 cells/mouse) enriched for CD41 T
cells (.92%) and depleted of CD81 T cells and B2201, F4/801,
Mac-11, and 33D11 cells (,0.4%) using mAb-coated immuno-
beads and affinity columns (R&D Systems).
Diabetes. Diabetes was assessed by measuring urine glucose
levels with Diastix strips (Miles, Ontario, Canada) twice a week.
Animals were considered diabetic after two consecutive readings
>31.
Histopathology. Submandibular salivary gland, thyroid, adre-
nal gland, kidney, liver, stomach, small intestine, colon, pancreas
(one half), and muscle were fixed in formalin, embedded in paraf-
fin, sectioned at 4.5 mM, stained with hematoxylin and eosin, and
examined for inflammation. The degree of insulitis in the pan-1666 Autoimmune Diabetes in Monoclonal T Cell NOD Mice
creas was evaluated by scoring 15–30 islets/mouse in a blinded
fashion using the following criteria: 0, normal islet; 1, periinsuli-
tis; 2, mononuclear cell infiltration in ,25% of the islet; 3,
mononuclear cell infiltration in 25–50% of the islet; 4, .50% of
the islet infiltrated. A second half of each pancreas was snap fro-
zen in liquid nitrogen, immersed in OCT, sectioned at 6–7 mM,
fixed in cold acetone for 10 min, and stained with anti-CD4
(GK1.5) and anti-CD8 (53-6.7) mAbs followed by anti–rat IgG-
FITC, or with anti–rat IgG-FITC alone, and observed under a
fluorescence microscope (26).
Statistical Analyses. Statistical analyses were performed using
Mann-Whitney U and x2 tests.
Results
Expression of the 8.3-TCR in 8.3-NOD Mice. Three-color
cytofluorometric studies showed that .97% CD42CD81
thymocytes (Fig. 1 A) and lymph node CD81 T cells (Fig.
1 B) from 8.3-NOD mice expressed Vb8.1/8.21 TCRs, as
compared with 18% of the CD42CD81 thymocytes and
lymph node CD81 T cells from nontransgenic NOD mice,
indicating TCR-b transgene expression. Although we do
not have a TCR-a–transgenic chain–specific mAb, and
thus cannot directly quantitate its expression, three differ-
ent lines of evidence indicate that the transgenic TCR-a
chain is expressed on a significant fraction of thymocytes
and peripheral T cells from 8.3-NOD mice. First, z67% of
CD41CD81 thymocytes from 8.3-NOD mice expressed
high levels of the transgenic TCR-b chain, as compared to
only 18% of CD41CD81 thymocytes from TCR-b–trans-
genic NOD mice, suggesting early TCR-a chain expres-
sion and early upregulation of TCR-a/b heterodimers on
immature thymocytes (38–42). Second, thymocyte devel-
opment in 8.3-NOD mice, but not 8.3–TCR-b–trans-
Figure 1. Expression of the TCR-a/b transgenes in 8.3-NOD mice. CD4, CD8, and Vb8.1/8.2 profiles of thymocytes (A) and lymph node cells (B)
from nontransgenic NOD, 8.3–TCR-b–transgenic NOD, and 8.3-NOD mice. (Top) CD4 versus CD8 contour plots of cell suspensions stained with
anti-CD8-PE, anti-V b8.1/8.2-FITC, and anti-CD4-biotin plus Streptavidin-PerCP. The lower panels show the Vb8.1/8.2 fluorescence histograms of
each T cell subset after electronic gating. Numbers indicate the average percentage of cells (top) or the average number of Vb8.1/8.21 cells (bottom) in
each subset. Data correspond to 3–9 mice/group. DP, double-positive cells; DN, double-negative cells.1667 Verdaguer et al.
genic NOD mice, was skewed towards the CD42CD81
subset (Fig. 1 A), suggesting TCR-a–transgene–dependent
positive selection of 8.3-CD81 thymocytes as in other
MHC class I–restricted TCR-a/b–transgenic models (38,
41, 43). As a result, the lymph nodes of 8.3-NOD mice
consistently had many more CD81 T cells (.65%) and
fewer CD41 T cells (,15%) than the lymph nodes of 8.3–
TCR-b–transgenic and nontransgenic NOD mice (with
,25% CD81 T cells and .40% CD41 T cells) (Fig. 1 B).
Finally, introduction of the 8.3–TCR-a and –TCR-b
transgenes into RAG-22/2 NOD mice, which cannot re-
arrange endogenous TCR genes, resulted in the positive se-
lection of CD81, but not CD41, Vb8.1/8.21 T cells (see
below). Taken together, these data indicate that the 8.3-
TCR is expressed on a significant fraction of thymocytes
and peripheral T cells from 8.3-NOD mice, and that 8.3–
TCR-a/b–transgene expression fosters the positive selec-
tion of CD81 T cells.
Functional Responsiveness and Activation State of Peripheral
CD81 T Cells in 8.3-NOD Mice. To investigate whether
peripheral T cells displaying the 8.3-TCR were function-
ally responsive to beta cells, we compared the proliferative
activity of CD41 T cell–depleted splenic CD81 T cells
from 8.3-NOD and 8.3–TCR-b–transgenic NOD mice in
response to irradiated NOD islet cells. As shown in Fig. 2 A,
CD81 T cells from 8.3-NOD, but not 8.3–TCR-b–trans-
genic NOD mice, proliferated vigorously in these assays,
both in the presence and absence of exogenous rIL-2. The
increased proliferative activity of splenic CD81 T cells
from 8.3-NOD versus 8.3–TCR-b–transgenic NOD mice
resulted from an increased frequency of beta cell–reactive
CD81 T cells (measured at z1/17 versus 1/4,000 splenic
CD81 T cells, respectively; Fig. 2 B), rather than from dif-
ferences in their general proliferative activity, since CD81
T cells from both types of mice proliferated equally well in
Figure 2. Responsiveness and peripheral frequency of beta cell–specific
CD81 T cells in 8.3-NOD mice. (A) Proliferation of splenic CD81 T
cells from 8.3-NOD and 8.3–TCR-b–transgenic NOD mice to islet
cells. 2 3 104 splenic CD81 T cells were incubated with g-irradiated islet
cells for 3 d, pulsed with [3H]thymidine, harvested, and counted. Bars
show the standard error of the means. (B) Peripheral frequency of beta
cell–reactive CD81 T cells in 8.3-NOD and 8.3–TCR-b–transgenic
NOD mice. 12 replicate cultures of serial dilutions of splenocytes (101–
105 cells/well) were stimulated with irradiated NOD islets (8/well) for 4 d,
expanded in rIL-2 (0.5 U/ml) for 10 d and restimulated once with islets
and rIL-2. The cultures were then challenged with 104 NIT-1 or L929-Kd
cells for 24 h, and the supernatants collected to measure their TNF-a
content. Cultures that secreted TNF-a in response to NIT-1, but not
L929-Kd, cells were considered to contain beta cell–reactive CD81 T cells.
(C) General proliferative activity of splenic CD81 T cells of 8.3-NOD
and 8.3–TCR-b–transgenic NOD mice. 2 3 104 splenic CD81 T cells
were incubated with 10-fold serial dilutions of plate-bound KJ16 in
rIL-2–containing CM for 3 d, pulsed with [3H]thymidine, harvested, and
counted.
Table 1. Secretion of TNF-a by Splenic- and Islet-derived CD81 
T Cells from 8.3-TCR-transgenic NOD Mice (pg/ml)
Effector
Target
MIN6N8a L929-Kd
pg/ml pg/ml
Naive
TCR-ab–TG ,1 ,1
TCR-b–TG ,1 ,1
a-CD3–activated*
TCR-ab–TG 300 ,10
TCR-b–TG ,1 ,10
Islet-derived‡
TCR-ab–TG 1,000 ,1
TCR-b–TG 250 ,1
CD81 T cells (104) were cultured with NOD-derived insulinoma cells
(MIN6N8a) or H-2Kd–transfected L929 cells (L929-Kd) (104) for 24 h.
The concentration of TNF-a in the supernatants was determined with
a bioassay using WEHI clone 14 cells as indicators. TG, transgenic.
*Activated with plate-bound anti-CD3 mAb (10 mg/ml) for 3 d and
expanded with rIL-2 for 7 d.
‡From diabetic mice within 3 d of diabetes onset.1668 Autoimmune Diabetes in Monoclonal T Cell NOD Mice
response to a plate-bound anti-Vb8.1/8.2 mAb (KJ16; Fig.
2 C). Therefore, 8.3-NOD mice export numerous beta
cell–specific CD81 T cells to the periphery, and these au-
toreactive CD81 T cells are not tolerant to antigen stimula-
tion in vitro.
Three-color cytofluorometric analyses of splenic CD81
T cells from diabetic 8.3-NOD and nontransgenic NOD
mice with mAbs against memory and activation markers
(CD25, CD44, CD69, and CD62L2) did not reveal any
significant differences (data not shown), suggesting that the
numerous beta cell–reactive CD81 T cells of 8.3-NOD
mice are quiescent. This was further investigated by com-
paring the ability of naive splenic CD81 T cells from 8.3-
NOD and 8.3–TCR-b–transgenic NOD mice to secrete
TNF-a in response to stimulation with beta cells. As shown
in Table 1, splenic CD81 T cells from 8.3-NOD mice did
not secrete TNF-a when challenged with NOD-derived
beta cells unless they had been previously activated in vitro
with plate-bound anti-CD3 mAb and rIL-2. As expected,
islet-derived CD81 T cells from both 8.3-NOD and 8.3–
TCR-b–transgenic NOD mice (enriched for in vivo–acti-
vated beta cell–specific CD81 T cells) secreted high levels
of TNF-a when challenged with NOD beta cells, but not
L929-Kd fibroblasts. It thus appears that the beta cell–reac-
tive CD81 T cells of 8.3-NOD mice do not undergo
spontaneous activation in the periphery.
Acceleration of Diabetes in 8.3-NOD Mice. We next in-
vestigated whether positive selection of the beta cell–spe-
cific 8.3-TCR in 8.3-NOD mice had any pathogenic sig-
nificance. We therefore followed 8.3-NOD mice of the
N3-N6 backcrosses of the founder mice onto the NOD
background for development of diabetes, and compared the
cumulative incidence curves of these mice with those of
nontransgenic NOD mice and 8.3–TCR-b–transgenic NOD
mice (26). As shown in Fig. 3 A, female and male 8.3-NOD
mice developed diabetes much earlier than female and male
8.3–TCR-b–transgenic (N4-N7), nontransgenic NOD lit-
termates (N3-N5) or NOD/Lt mice (ages at onset: 43 6
10 versus 88 6 12, 120 6 19 and 119 6 26 d, respectively,
for females, P ,0.0001; and 66 6 15 versus 109 6 33, 173
6 35, and 157 6 28 d, respectively, for males, P ,0.0001).
Despite the dramatic acceleration of diabetes onset in 8.3-
NOD mice, the cumulative incidence of diabetes and the ki-
netics of disease penetrance in the 8.3-NOD, 8.3–TCR-
b–transgenic, nontransgenic NOD littermates, and NOD/
Lt mouse populations were remarkably similar (females:
73.1% versus 86, 78, and 84%, respectively; males: 50%
versus 50, 31, and 46%, respectively; Fig. 3 A). No major
differences in disease penetrance were noted among 8.3-
NOD mice of the N3-N6 generations. In females, for ex-
ample, the incidence and age at onset of diabetes for each
generation were: N3, 6/8 mice at 40 6 4 d; N4, 5/6 mice
Figure 3. 8.3–TCR-a/b–
transgene expression and diabe-
togenesis. (A) Incidence of
IDDM in female (26 8.3–, 21
8.3–TCR-b–transgenic, and 114
nontransgenic) and male (24
8.3–, 30 8.3–TCR-b–trans-
genic, and 59 nontransgenic)
NOD mice. (B) Progression of
insulitis in nontransgenic, 8.3–
TCR-b–transgenic, and 8.3-
NOD mice (4–7 mice/age group;
15–30 islets/mouse). Bars show
the standard deviation of the
means. *, P ,0.0001 (Mann-
Whitney U test). (C) Flow cy-
tometry profile of islet-derived T
cells from diabetic 8.3-NOD
mice. Islets from acutely diabetic
8.3-NOD mice were cultured in
rIL-2–containing CM for 3–5 d
and the resulting cells studied by
flow cytometry as in Fig. 1. (D)
Phenotype of islet-infiltrating T
cells in 8.3-NOD versus non-
transgenic NOD mice. Pancreas
sections were stained with anti-
CD8 (53.6-7) or anti-CD4
(GK1.5) mAbs and FITC-labeled
anti–rat IgG, and observed under
a fluorescence microscope. Orig-
inal magnification: 200.1669 Verdaguer et al.
at 45 6 6 d; N5, 2/3 mice at 37 6 3 d; and N6, 6/9 mice
at 51 6 13 d. The same was true for 8.3–TCR-b–trans-
genic NOD mice (26), and for nontransgenic NOD litter-
mates (N3 females: 3/3 mice at 140 6 5 d; N4 females: 6/
8 mice at 117 6 46 d; and N5 females: 5/7 mice at 117 6
14 d). Taken together, these data indicate that the 8.3-
TCR is highly diabetogenic in the NOD background, and
suggest that the events that trigger diabetes in 8.3-NOD
mice are similar to those that trigger diabetes in nontrans-
genic NOD mice.
Pathogenic Basis of Disease Acceleration in 8.3-NOD
Mice. To elucidate the mechanisms underlying disease accel-
eration in 8.3-NOD mice, we followed the progression of
insulitis in 3–6-wk-old 8.3-NOD, 8.3–TCR-b–transgenic
and nontransgenic NOD mice. Unexpectedly, the insulitis
scores of 3-wk-old 8.3-NOD mice were significantly lower
than the insulitis scores of age-matched 8.3–TCR-b–trans-
genic and nontransgenic NOD mice (Fig. 3 B). In contrast,
the insulitis scores of 6-wk-old 8.3-NOD mice were sig-
nificantly more severe than those of 8.3–TCR-b–trans-
genic and nontransgenic NOD mice (Fig. 3 B). It thus ap-
pears that insulitis in 8.3-NOD mice starts later, but progresses
much faster, than in 8.3–TCR-b–transgenic and nontrans-
genic NOD mice. As expected, most of the islet-derived T
cells of acutely diabetic 8.3-NOD mice were CD81 and
expressed the transgene-encoded Vb8.1 element (Fig. 3
Figure 4. Diabetogenesis in
TCR-transgenic RAG-22/2
NOD mice. (A) Flow cytometry
profiles of lymph node cells from
RAG-22/2 4.1-NOD mice (left)
and RAG-22/2 8.3-NOD mice
(right). (B) Incidence of diabetes
in RAG-22/2 4.1-NOD (n 5
29 females and 35 males), RAG-
22/2 8.3-NOD (n 5 12 females
and 20 males), and RAG-22/2
NOD mice (n 5 20 females and
20 males). The few cells of the
opposite T cell subset that appear
in the flow cytometry profiles of
these mice are the result of non-
specific staining of dead cells. (C)
Phenotype of islet-infiltrating T
cells in RAG-22/2 4.1-NOD
and RAG-22/2 8.3-NOD mice.
Most of the few CD81 T cells in
RAG-22/2 4.1-NOD mice, and
the few CD41 T cells in RAG-
22/2 8.3-NOD mice were the
result of background staining, as
they were also seen in anti–rat
IgG-FITC–stained tissue.1670 Autoimmune Diabetes in Monoclonal T Cell NOD Mice1671 Verdaguer et al.
C). Immunopathological studies of pancreata from these
mice confirmed that the insulitis lesions of 8.3-NOD mice
contained many more CD81 T cells, and fewer CD41 T
cells, than the lesions of nontransgenic (Fig. 3 D) and 8.3–
TCR-b–transgenic NOD mice (26). Between 3 and 27%
of all the islet-derived, beta cell–reactive CD81 T cell
clones from these mice (but 0% of the spleen-derived, beta
cell–reactive CD81 T cell clones) contained serine esterase
activity and were cytotoxic to NOD (H-2Kd, Db), but not
C57BL/6 (H-2Kb, Db) islet cells in vitro (data not shown).
We thus conclude that acceleration of diabetes in 8.3-NOD
mice results from massive recruitment of highly diabeto-
genic, beta cell–cytotoxic CD81 T cells (and CD41 T cells) to
pancreatic islets early in the disease process.
Spontaneous Diabetes in Monoclonal 8.3-NOD and 4.1-
NOD Mice. Comparison of the natural history of diabetes
in 8.3-NOD mice to that in mice expressing the TCR re-
arrangements of a beta cell–specific, I-Ag7–restricted CD41
T cell clone (4.1-NOD mice) (33), revealed a remarkable
similarity (i.e., similar acceleration of the disease). To in-
vestigate whether the highly diabetogenic CD81 and CD41
T cells of these mice could spontaneously accumulate in
pancreatic islets, differentiate into beta cell–cytotoxic effec-
tors, and destroy beta cells in the absence of T cells display-
ing endogenous TCRs, we introduced the 8.3- and 4.1-
TCR transgenes into RAG-22/2 NOD mice, which cannot
rearrange endogenous TCR or Ig genes (34). As expected,
virtually all of the lymph node T cells of RAG-22/2 4.1-
NOD mice and RAG-22/2 8.3-NOD mice were CD41
Vb111 or CD81Vb8.1/8.21 T cells, respectively (Fig. 4 A).
Surprisingly, RAG-22/2 4.1-NOD mice developed dia-
betes slightly earlier than, and almost as frequently as,
RAG-21 4.1-NOD mice (ages at onset: 36 6 10 versus 44 6
13 d for females; and 39 6 13 versus 56 6 27 d for males;
incidences of 72 versus 76% for females, and 60 versus 73%
for males, respectively). In contrast, RAG-22/2 8.3-NOD
mice developed diabetes much less frequently (33 versus
73% for females, P ,0.0001; and 26 versus 50% for males,
P  ,0.0001), and significantly later than RAG-21 8.3-
NOD mice (ages at onset: 111 6 16 versus 43 6 10 d for fe-
males, P ,0.002; and 94 6 50 versus 66 6 15 d for males,
P ,0.05). We are confident that insulitis and diabetes in
RAG-22/2 4.1-NOD and RAG-22/2 8.3-NOD mice were
triggered by T cells expressing the transgenic TCRs, for
two reasons. First, nontransgenic RAG-22/2 NOD mice
developed neither diabetes (Fig. 4 B) nor insulitis (data not
shown). Second, the pancreatic islets of diabetic RAG-22/2
4.1-NOD and RAG-22/2 8.3-NOD mice almost exclu-
sively contained CD41 or CD81 T cells, respectively (Fig.
4 C). A few cells of the opposite T cell subset were also
seen in these mice (Fig. 4 C); however, these cells were
probably the result of background staining since they were
also seen in sections stained with anti–rat IgG-FITC alone
(data not shown). These results demonstrate that (a) 4.1-
CD41 T cells can accumulate efficiently in pancreatic islets
and trigger diabetes in the absence of mature B cells and
T cells expressing endogenous TCRs, and (b) although 8.3-
CD81 T cells can also cause diabetes in the absence of B
cells and T cells expressing endogenous TCRs, they do so
much less efficiently than in their presence.
Absence of Extra-pancreatic Pathology in TCR-transgenic
RAG-22/2 NOD Mice. Since nontransgenic NOD mice
can also develop inflammation of other organs, notably the
submandibular salivary glands and the thyroid (44), we in-
vestigated the presence of sialitis in diabetic TCR-transgenic
RAG-22/2 NOD mice. Sialitis was invariably present in all
the 8.3-NOD, 4.1-NOD, and nontransgenic NOD mice that
were investigated (n 5 2–7 mice/group), but completely
absent in RAG-22/2 NOD, RAG-22/2 4.1-NOD, and
RAG-22/2 8.3-NOD mice (n 5 7–10 mice/group). In-
flammation of the thyroid, adrenal glands, kidney, liver, gut,
stomach, or muscle was also absent in all these mice. It thus
appears that the inflammatory potential of 4.1-CD41 and
8.3-CD81 T cells is tissue specific.
Normal CD81 T Cell Development but Slow Progression of
Insulitis in RAG-22/2 8.3-NOD Mice. Experiments were
next performed to elucidate the mechanisms underlying
disease deceleration in RAG-22/2 8.3-NOD versus RAG-
21 8.3-NOD mice. Three-color cytofluorometric studies
using mAbs against several differentiation markers, includ-
ing the transgenic TCR, MHC class I (Kd), CD5, CD24,
CD44, and CD69, revealed that the CD41CD81 and
CD42CD81 thymocytes of RAG-22/2 8.3-NOD mice
and RAG-21 8.3-NOD mice were phenotypically similar
(Fig. 5 A). Likewise, no phenotypic differences were noted
between the peripheral CD81 T cells of RAG-22/2 8.3-
NOD mice and those of RAG-21 8.3-NOD mice with re-
spect to several markers, including Vb8.1/8.2, CD2, CD11a,
CD28, CD44, CD45RB, CD62L and CD69 (Fig. 5 B). Fur-
thermore, splenic CD81 T cells from both types of mice
proliferated equally well in response to islet cells in vitro
(Fig. 5 C). It thus appears that the 8.3-CD81 T cells of
RAG-22/2 8.3-NOD mice are phenotypically and func-
tionally similar to those of RAG-21 8.3-NOD mice.
We then investigated whether the islet-derived CD81 T
cells of RAG-22/2 8.3-NOD mice had differentiated into
Th1-like CTLs (Tc1) in situ. We first isolated CD81 T
cells from the pancreatic islets of acutely diabetic RAG-21
8.3-NOD and RAG-22/2 8.3-NOD mice and determined
their cytokine profile by reverse transcription-PCR. As shown
Figure 5. Phenotype and functional activity of CD81 T cells from RAG-22/2 versus RAG-21 8.3-NOD mice. (A) Flow cytometry profiles of
CD41CD81 (left) and CD42CD81 thymocytes (right) from 8.3-NOD mice (dotted line) and RAG-22/2 8.3-NOD mice (solid line) for maturation mark-
ers. Thymocytes were analyzed by three-color cytofluorometry as in Fig. 1. Panels show the fluorescence histograms of each marker on gated
CD41CD81 and CD42CD81 thymocytes. (B) Flow cytometry profiles of splenic CD81 T cells from 8.3-NOD mice (dotted line) and RAG-22/2 8.3-
NOD mice (solid line) for activation and memory markers. (C) Proliferative activity of splenic CD81 T cells from 8.3-NOD mice and RAG-22/2 8.3-
NOD mice in response to islet cells. (D) Reverse transcription-PCR analysis for cytokine gene expression of islet-derived CD81 T cells from 8.3-NOD
mice and RAG-22/2 8.3-NOD mice. M, 1Kb ladder. (E) Kinetics of insulitis in RAG-22/2 8.3-NOD mice.1672 Autoimmune Diabetes in Monoclonal T Cell NOD Mice
in Fig. 5 D, the islet-derived CD81 T cells of both types of
mice transcribed messenger RNA for IL-2, IFN-g, IL-10,
and TNF-a, but not IL-4. We then determined the per-
centage of serine esterase–containing T cell clones among
those capable of secreting TNF-a specifically in response to
NOD beta cells shortly after their isolation from islets. In-
terestingly, the percentage of serine esterase–positive clones
per mouse was, on average, greater than that observed in
8.3-NOD mice (43 versus 13%; data not shown). Thus,
lack of CTL generation does not appear to account for the
relative diabetes resistance of RAG-22/2 8.3-NOD mice.
Finally, to determine whether deceleration of diabetes in
RAG-22/2 8.3-NOD mice resulted from slow progression
of insulitis, we scored the degree of insulitis in cohorts of
5–35-wk-old nondiabetic RAG-22/2 8.3-NOD mice. We
found that most of these mice had very mild or no insulitis
and that, when present, it progressed much slower than in
RAG-21 8.3-NOD mice (compare Figs. 5 E and 3 B). It
thus appears that the rate-limiting factor of diabetogenesis
in RAG-22/2 8.3-NOD mice is the ability of these mice
to develop insulitis.
CD41 T Cells Can Trigger the Recruitment of Naive
CD81 T Cells in RAG-22/2 8.3-NOD Mice. To investi-
gate whether nontransgenic splenocytes other than CD81
T cells could foster the recruitment of the diabetogenic
8.3-CD81 T cells of RAG-22/2 8.3-NOD mice into islets,
we transfused CD81 T cell–depleted splenocytes from young
nontransgenic NOD mice into RAG-22/2 8.3-NOD mice
or RAG-22/2 NOD mice. As shown in Table 2, spleen
cell–transferred RAG-22/2 8.3-NOD mice developed se-
vere insulitis, owing to massive infiltration of islets by B
cells and CD41 and CD81 T cells, and four of five mice
developed diabetes shortly after transfer (at 36 6 16 d). In
contrast, none of the seven spleen cell–transfused RAG-22/2
NOD mice had developed diabetes or insulitis by 8–10 wk
after transfer. To ascertain whether diabetes in RAG-22/2
8.3-NOD mice was triggered by CD41 T cells, we injected
purified splenic CD41 T cells from young nontransgenic
NOD mice into two RAG-22/2 8.3-NOD mice. As shown
in Table 2, both mice developed severe insulitis (contain-
ing CD41 and CD81 T cells, but not B cells) and diabetes
shortly after transfer (35 6 22 d). These results demonstrate
that the peripheral naive CD81 T cells of RAG-22/2 8.3-
NOD mice can be induced to migrate into pancreatic islets
by splenic CD41 T cells from nontransgenic NOD mice.
Discussion
Although it is well established that IDDM is a T lym-
phocyte–dependent autoimmune disease, the role of partic-
ular T cell subsets in the disease process remains a matter of
intense debate. The emerging consensus, however, seems
to be that diabetogenesis is initiated by autoreactive CD81
T cells, that its progression requires the recruitment of au-
toreactive CD41 T cells, and that clinically relevant beta cell
destruction is effected by both CD41 and CD81 T cells re-
cruited to the site later on in the process (45). This postu-
late would predict that naive, but potentially diabetogenic,
autoreactive CD81 T cells would be able to home into pan-
creatic islets and affect beta cell damage in the absence of
other T cell specificities. Here we have tested this hypothe-
sis by comparing the ability of TCR transgenes derived from
beta cell–specific CD81 or CD41 T cells to trigger and/or
to accelerate diabetogenesis in RAG-21 and/or RAG-22/2
TCR-transgenic NOD mice. We have shown that both
TCR transgenes have similar diabetogenic potential when
expressed in wild-type NOD mice, but not when ex-
pressed in RAG-22/2 NOD mice; although CD41 T cells
expressing the 4.1-TCR remained highly diabetogenic when
maturing in the absence of endogenous T cells, CD81 T
cells expressing the 8.3-TCR did not. We have also shown
that these autoreactive CD81 T cells do not require CD41
T cell help to mature properly, to proliferate in response to
antigenic stimulation, or to differentiate into CTLs, but
that they require a CD41 T cell–derived signal to efficiently
home into pancreatic islets and effect clinically relevant beta
cell damage.
Expression of the TCR-a and -b rearrangements of the
beta cell–cytotoxic CD81 T cell clone NY8.3 in NOD
mice skewed T cell development towards the CD81 T cell
Table 2. Nontransgenic CD41 T Cells Can Trigger the Recruitment and Activation of Autoreactive CD81 T Cells in RAG-22/2 8.3-
NOD Mice
Cells Recipient n IDDM‡ (n) Insulitis (n)
Cells in Lesion
B2201 CD41 CD81
CD81 depleted* RAG-22/2 NOD 7 0/7 0 (3) ND
RAG-22/2 8.3-NOD 5 4/5 3.2 6 0.3 (4) 111 11 111
CD41§ RAG-22/2 8.3-NOD 2 2/2 3.4 6 0.2 (2) 1/2 111 111
*Splenocytes from 4–5-wk-old nontransgenic female NOD mice were depleted of CD81 T cells using anti-CD8 mAb (53-6.7)–coated magnetic
beads, as described (26). 8 3 106 cells (containing ,0.5% CD81 T cells) were injected into 5–8-wk-old female mice.
‡8–10 wk after transfer.
§Splenic T cells from nontransgenic female NOD mice were enriched for CD41 T cells (.92%) and depleted of CD81 T cells and B2201, F4/801,
Mac-11, and 33D11 cells (,0.4%) using mAb-coated immunobeads and affinity columns. Each mouse received 1.5 3 107 cells.1673 Verdaguer et al.
subset, as expected, and accelerated the onset of IDDM by
several months, as a result of massive recruitment of naive
CD81 (and CD41) T cells into pancreatic islets. Since the
8.3-TCR uses a TCR-a–CDR3 sequence that is highly
homologous to that of TCRs used by many NOD islet-
derived beta cell–cytotoxic CD81 T cells (25), we are con-
fident that this TCR is representative of a large fraction of
MHC class I–restricted autoreactive TCRs recruited to pan-
creatic islets in spontaneous IDDM. The dramatic accelera-
tion of diabetes in 8.3-NOD mice was not surprising, since
it was consistent with the less dramatic, but significant, ac-
celeration of diabetes that we had seen in transgenic NOD
mice expressing only the TCR-b rearrangement of NY8.3
(26). The observation that disease acceleration occurred in
8.3-NOD and 8.3–TCR-b–transgenic NOD mice seemed,
at first, to support the hypothesis that autoreactive CD81 T
cells play a critical role in disease initiation. This hypothesis,
which is largely based on the observation that b2-micro-
globulin–deficient (17–19) and anti-CD8 mAb-treated NOD
mice (20) develop neither diabetes nor insulitis, proposes
that CD81 T cells affect the initial beta cell insult that ex-
poses beta cell autoantigens to APCs and diabetogenic
CD41 T cells in autoimmune diabetes. Two other observa-
tions in 8.3-NOD and 8.3–TCR-b–transgenic NOD mice,
however, argued against this scenario. First, the age at onset
of insulitis in 8.3-NOD mice was delayed when compared
to the age at onset of insulitis in 8.3–TCR-b–transgenic
and nontransgenic NOD mice, which have many fewer
beta cell–reactive CD81 T cells than 8.3-NOD mice. Sec-
ond, despite the large abundance of beta cell–reactive CD81
T cells in the peripheral lymphoid organs of 8.3-NOD
mice, and the dramatic acceleration of diabetes onset, the
overall incidence of diabetes in these mice was virtually
identical to that seen in 8.3–TCR-b–transgenic and non-
transgenic NOD mice. These observations, which are rem-
iniscent of the inability of splenic CD81 T cells from dia-
betic NOD mice to transfer insulitis into NOD.scid mice
(6), suggested that autoreactive (8.3-like) CD81 T cells
might function more as effectors of beta cell damage, than
as initiators of diabetogenesis. The invariable presence of
beta cell–cytotoxic CD81 T cells in pancreatic islets of pre-
diabetic and acutely diabetic nontransgenic NOD mice
(21–25), and the ability of some islet-derived CD81 CTL
clones to effect beta cell destruction in vivo in the absence
of CD41 T cells (16, 32), are compatible with this view.
Studies of RAG-22/2 8.3-NOD mice provided addi-
tional support for this interpretation of the data; these mice
developed diabetes less frequently and significantly later than
8.3-NOD mice, thus indicating that 8.3-CD81 T cells had
lost most of their diabetogenic potential in the absence of B
cells and endogenous T cells. Cytofluorometric and func-
tional studies of thymic and peripheral 8.3-CD81 T cells of
RAG-22/2 8.3-NOD and 8.3-NOD mice indicated that
deceleration of diabetes in RAG-22/2 8.3-NOD mice was
not due to abnormal maturation of 8.3-CD81 T cells, to
their inability to proliferate in response to beta cell autoan-
tigen in vitro, or to their inability to differentiate into beta
cell–cytotoxic effectors in the absence of CD41 Th cells.
The fact that 8.3-CD81 T cells are not dependent on CD41
Th cells for proliferation and differentiation into CTLs is sur-
prising, but not unprecedented. MHC class II–deficient (46)
or CD4-deficient (47) mice, for example, have decreased
helper activity for antibody responses, but have unimpaired
CTL responses against viruses. Alternatively, the in vitro
beta cell–cytotoxic potential of the islet-derived CD81 T
cells of these mice is not acquired in vivo and is an artifact
of in vitro manipulation, a possibility that we cannot rule out
at present. Whether this is the case or not, our data suggest
that decelerated diabetogenesis in RAG-22/2 8.3-NOD
mice results from a difficulty of naive 8.3-CD81 T cells to
home into and/or accumulate in pancreatic islets in the ab-
sence of CD41 T cells; nondiabetic mice did not have, or
only had a low degree of, insulitis, and splenic CD41 T cells
from nontransgenic NOD mice were able to trigger the re-
cruitment of diabetogenic 8.3-CD81 T cells into pancre-
atic islets when transfused into RAG-22/2 8.3-NOD mice.
There are several possible mechanisms by which CD41
T cells may foster the recuitment and/or accumulation of
8.3-CD81 T cells in islets. CD41 T cells, and/or the nu-
merous macrophages that are recruited to the site by CD41
T cells (our unpublished observation), may secrete cyto-
kines and/or chemokines that are essential for the recruit-
ment of naive CD81 T cells to the site (48). The observation
that certain activated, beta cell–reactive CD81 clones can
transfer diabetes into NOD.scid mice in the absence of CD41
T cells (16) is not incompatible with this view; the homing
potential of lymphocytes is a function of their activation
state (49). An alternative, but not mutually exclusive, possi-
bility is that since beta cells do not express B7 costimulatory
molecules (30), which are essential in T cell activation and
differentiation, accumulation of 8.3-CD81 T cells in islets
may require the shedding of their target beta cell autoanti-
gen by a CD41 T cell–mediated beta cell insult followed by
its presentation by APCs capable of diverting exogenous
antigens to the MHC class I antigen-processing pathway
(e.g., dendritic cells; reference 50). The fact that some
RAG-22/2 8.3-NOD mice do develop diabetes does not
necessarily argue against this scenario; because of their un-
naturally high frequency, some of the beta cell–reactive
CD81 T cells of these mice may undergo activation in re-
sponse to cross-reactive antigens or to autoantigenic mole-
cules that are occasionally shed from beta cells even in the
absence of any autoimmune-mediated beta cell damage.
The nature and specificity of the CD41 T cells that may
affect the initial beta cell insult that results in the recruit-
ment and activation of naive MHC class I–restricted CD81
T cells (8.3-like) and other beta cell–cytotoxic effectors in
spontaneous IDDM is unknown. Although studies of indi-
vidual TCR specificities do not allow to draw definitive
conclusions about the relative roles of CD41 versus CD81
T cells in the initiation of autoimmune diabetes, four dif-
ferent lines of evidence suggest that 4.1-like CD41 T cells
may be capable of playing such a role. First, insulitis in 4.1-
NOD mice appeared earlier than in 8.3-NOD mice (33).
Second, 4.1-NOD developed diabetes more frequently than,
but as early as, 8.3-NOD mice (33). Third, RAG-22/21674 Autoimmune Diabetes in Monoclonal T Cell NOD Mice
4.1-NOD mice developed diabetes as frequently and as
early as 4.1-NOD mice, demonstrating that, unlike 8.3-
CD81 T cells, 4.1-CD41 T cells can efficiently home into
and accumulate in pancreatic islets, differentiate into effec-
tor cells, and cause diabetes without the assistance of B cells
or other T cells. Finally, and most importantly, the 4.1-
TCR has the unique ability of engaging several distinct
MHC class II molecules on thymic bone marrow–derived
APCs with consequences that are highly reminiscent of the
MHC class II–linked resistance of nontransgenic mice to
insulitis and diabetes; antidiabetogenic MHC class II mole-
cules can prevent the development of insulitis and diabetes
by abrogating the development of 4.1-like CD41 T cells
(33). The above hypothesis that diabetogenesis might be
initiated by 4.1-like CD41 T cells is not incompatible with
the large body of evidence indicating that development of
insulitis in nontransgenic NOD mice requires CD81 T
cells and/or MHC class I molecules on beta cells (3–6, 17–
20, 27, 28). Development of full-blown insulitis in non-
transgenic NOD mice may require both an initial beta cell
insult by 4.1-like CD41 T cells and the immediate recruit-
ment and activation of MHC class I–restricted CD81 T
cells. As pointed out above for RAG-22/2 8.3-NOD mice,
the fact that diabetogenesis in RAG-22/2 4.1-NOD mice
bypasses the need for CD81 T cells does not contradict this
view; the high frequency of beta cell–reactive CD41 T cells
in 4.1-NOD mice may overwhelm the mechanisms that, in
nontransgenic NOD mice, would prevent these cells from
reaching an insulitogenic mass upon activation.
We do not yet know why 4.1-like CD41 T cells are so
highly diabetogenic; however, since beta cells do not nor-
mally express MHC class II molecules (14, 15), it would not
be unreasonable to speculate that the diabetogenic potential
of 4.1-CD41 T cells stems from their ability to strongly en-
gage autoantigen/I-Ag7 complexes that are already present
on the surface of local APCs before any previous beta cell
insult (e.g., secreted proteins). The fact that RAG-22/2
4.1-NOD mice do not develop sialoadenitis, which is in-
variably present in nontransgenic NOD mice, does indeed
suggest that both the recruitment and activation of 4.1-
CD41 T cells are driven by local APCs. Such a strong in-
teraction between local APCs and 4.1-CD41 T cells may
trigger the upregulation of Fas ligand on the T cells, en-
dowing them with the ability to kill bystander beta cells
that have been induced (perhaps by cytokines) to express
Fas (51). In fact, islet-derived 4.1-CD41 T cells from 4.1-
NOD mice are efficient killers of Fas cDNA-transfected fi-
broblasts in vitro (our unpublished observations). These ac-
tivated CD41 T cells may also be able to damage beta cells
by activating the cytocidal activity (free radical production
and cytokine secretion) of the numerous macrophages that
they recruit to the site.
Our results do not imply that diabetogenesis in nontrans-
genic NOD mice is initiated by cells expressing the 4.1-
TCR, nor do they rule out the possibility that there might
be CD81 T cell specificities with an independent ability to
home into pancreatic islets and affect the initial beta cell in-
sult before the recruitment of CD41 T cells into pancreatic
islets (i.e., those recruited to islets early in the disease pro-
cess; reference 16). However, the strikingly different natu-
ral histories of diabetes in RAG-22/2 8.3-NOD versus
RAG-22/2 4.1-NOD mice, and the ability of antidiabeto-
genic MHC class II molecules to prevent diabetogenesis in
4.1-NOD mice by interfering with the developmental bi-
ology of the highly diabetogenic 4.1-TCR, lend support to
our hypothesis that diabetogenesis in nontransgenic NOD
mice may be initiated by 4.1-like CD41 T cells, rather than
by 8.3-like CD81 T cells.
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